A-RAF blocking peptide

Phospho-A-RAF (Ser582) Blocking Peptide

Cat. Num. AAA9618293

• Gene Names: ARAF; PKS2; A-RAF; ARAF1; RAFA1
• Applications: Blocking/Control
• Purity: The purity is >90%,tested by HPLC and MS.
• Synonyms: A-RAF; Phospho-A-RAF (Ser582) Blocking Peptide; A raf 1; A Raf proto oncogene serine/threonine protein kinase; ARAF 1; Araf; ARaf proto oncogene serine/threonine protein kinase; ARAF_HUMAN; ARAF1; Oncogene Araf1; Oncogene PKS2; PKS 2; PKS; PKS2; Proto oncogene Pks; Proto-oncogene A-Raf; Proto-oncogene A-Raf-1; Proto-oncogene Pks; RAFA 1; RAFA1; Ras binding protein DA Raf; Serine/threonine-protein kinase A-Raf; v raf murine sarcoma 3611 viral oncogene homolog; v raf murine sarcoma 3611 viral oncogene homolog 1; v raf oncogene homolog 1 (murine sarcoma 3611 virus); A-RAF blocking peptide

• Purity/Purification: The purity is >90%,tested by HPLC and MS.
• Form/Format: Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.

• Applicable Applications for A-RAF blocking peptide: Blocking/Control
• Notes: For phospho antibody, we provide phospho peptide (0.5mg) and non-phospho peptide (0.5mg)
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Related Product Information for A-RAF blocking peptide

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.

NCBI and Uniprot Product Information

• NCBI GI #: 371875793
• NCBI GeneID: 369
• NCBI Accession #: NP_001243125.1
• NCBI GenBank Nucleotide #: NP_001243125.1
• UniProt Accession #: P10398; P07557; Q5H9B2; Q5H9B3
• Molecular Weight: 67,585 Da
• NCBI Official Full Name: serine/threonine-protein kinase A-Raf isoform 2
• NCBI Official Synonym Full Names: v-raf murine sarcoma 3611 viral oncogene homolog
• NCBI Official Symbol: ARAF
• NCBI Official Synonym Symbols: PKS2; A-RAF; ARAF1; RAFA1
• NCBI Protein Information: serine/threonine-protein kinase A-Raf; Oncogene ARAF1; proto-oncogene Pks; proto-oncogene A-Raf-1; Ras-binding protein DA-Raf; v-raf murine sarcoma 3611 viral oncogene homolog 1; A-Raf proto-oncogene serine/threonine-protein kinase
• UniProt Protein Name: Serine/threonine-protein kinase A-Raf
• UniProt Gene Name: ARAF
• UniProt Synonym Gene Names: ARAF1; PKS; PKS2
• UniProt Entry Name: ARAF_HUMAN

NCBI Description

This proto-oncogene belongs to the RAF subfamily of the Ser/Thr protein kinase family, and maybe involved in cell growth and development. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2012]

Uniprot Description

ARAF: a tyrosine kinase-like kinase of the RAF family. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Frequently mutated in thyroid cancers, skin melanomas and at lower frequency in a wide range of human cancers. An activating mutation, mimicking phosphorylation of the activation loop, is seen in 60% of malignant melanoma samples. Raf mutations are generally exclusive to Ras activating mutations. Activating mutations are also seen in ~10% of colorectal cancers, in lung cancers and gliomas, and at a lower rate in several other tumors. Inactivating mutations are also seen and may result in activation of c-Raf and Erk. Mutations in B-Raf, MEK1 and MEK2 also associated with cardiofaciocutaneous syndrome, displaying morphological, cardiac and mental defects. Approved Inhibitor: Nexavar/Sorafenib.

Protein type: Protein kinase, TKL; Protein kinase, Ser/Thr (non-receptor); Oncoprotein; Kinase, protein; EC 2.7.11.1; TKL group; RAF family

Chromosomal Location of Human Ortholog: Xp11.4-p11.2

Molecular Function: protein serine/threonine kinase activity; protein binding; metal ion binding; receptor signaling protein activity; ATP binding; protein kinase activity

Biological Process: regulation of proteasomal ubiquitin-dependent protein catabolic process; protein modification process; protein amino acid phosphorylation; positive regulation of peptidyl-serine phosphorylation; negative regulation of apoptosis; regulation of TOR signaling pathway